Top Markets
Coin of the day
NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP
株式のランク #18279
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
株価
$1.79
最終同期: 2026-09-02
時価総額
$205.75M
変化(1日)
3.18%
変化(1年)
-61.61%
US
取引 NovaBridge Biosciences (NBP)

カテゴリー

NovaBridge Biosciences(NBP)の株価履歴
終値の最高値: $1.76 (2026-09-01)

終値の最安値: $13.69 (2020-01-01)
NovaBridge Biosciences の株価履歴(2020 ~ 2026)
年間株価パフォーマンス
パフォーマンス
2026 (TTM) -24.42%
2025 320.81%
2024 -37.56%
2023 -57.87%
2022 -92.59%
2021 24.83%
2020 0.00%
類似企業または競合の株価
企業 株価 変化率 1年%
$556.43 40.29%
US
$1.05K 45.39%
NL
$152.82 535.43%
US
$123.05 -8.95%
AU
$757.71 6.76%
CH